Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients

BACKGROUND: Monoclonal antibodies (mAb), such as trastuzumab are a valuable addition to breast cancer therapy. Data obtained from neoadjuvant settings revealed that antibody-dependent cell-mediated cytotoxicity (ADCC) is a major mechanism of action for the mAb trastuzumab. Conflicting results still...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Petricevic, Branka, Laengle, Johannes, Singer, Josef, Sachet, Monika, Fazekas, Judit, Steger, Guenther, Bartsch, Rupert, Jensen-Jarolim, Erika, Bergmann, Michael
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2013
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4029549/
https://ncbi.nlm.nih.gov/pubmed/24330813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-307
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak